

EBMT Activity survey on HSCT in 2004: donor type and source

Donor	Source			Total
	BM	PBPC	Combined	
Allogeneic total	2305	5102	n.d.	7407
HLA-id	1303	2794	n.d.	4097
HLA-nid	76	356	n.d.	432
Twin	7	33	n.d.	40
Unrelated	919	1919	n.d.	2838
Autologous	321	14488	n.d.	14809

EBMT Activity survey on HSCT in 2004: patient and transplant numbers

Indication	Allogeneic HSCT	Autologous HSCT	Total
1st transplants = patients	7407	14809	22216
Retransplants	1048	790	1838
Additional transplants	501	2039	2540
TOTAL	8956	17638	26594

Final data 12/05



EBMT Activity survey on HSCT in 2004: main indications

Indication	Allogeneic 1st Tx.	Autologous 1st Tx.	Total
Leukaemias*	5524	1443	7045
Lymphomas	768	11121	12310
SAA	334	0	334
Solid tumours	123	1605	1759
Non-malignant disorders	604	77	681
Others	54	33	87
Total	7407	14279	22216

* includes CLL

Final data 12/05



EBMT Activity survey on HSCT in 2004: leukemias

Indication	Allogeneic 1 st Tx.	Autologous 1 st Tx.	Total
AML 1st CR	1354	874	2228
not 1st CR	1060	155	1205
ALL 1st CR	707	154	861
not 1st CR	673	72	749
CML cP	524	11	535
not cP	278	19	297
MDS (incl. Sec AL)	549	26	575
MPS	199	11	210
CLL	190	195	385

Final data 12/05



EBMT Activity survey on HSCT in 2004: lymphoproliferative disorders

Indication	Allogeneic 1 st Tx.	Autologous 1 st Tx.	Total
PCD - Myeloma	164	5324	5488
PCD - Other	11	214	225
HD	104	1546	1650
NHL	489	4458	4947

Final data 12/05



EBMT Activity survey on HSCT in 2004: solid tumors

Indication	Allogeneic 1 st Tx.	Autologous 1 st Tx.	Total
Neuroblastoma	4	369	373
Soft tissue	2	122	124
Germinal	0	307	307
Breast	10	190	200
Ewing	6	237	243
Renal cancer	61	31	92
Melanoma	1	1	2
Colon cancer	16	10	26
Others	23	369	392


EBMT Activity survey on HSCT in 2004: non malignant disorders

Indication	Allogeneic 1 st Tx.	Autologous 1 st Tx.	Total
BM aplasia – SAA	334	0	334
BM aplasia – Other	82	1	83
Hemoglob. – Thalassemia	160	0	160
Hemoglob. – Other	35	0	35
Immune deficiencies	247	4	251
Inherited dis. Metabolism	72	0	72
Auto immune	8	72	80


Final data 12/05




EBMT Activity survey on HSCCT 1990 - 2004: changes in stem cell source




Evolution of RIC HSCT in Europe 1990-2004




EBMT Activity survey on HSCT 1990 - 2004: changes in stem cell source by donor type



EBMT Activity survey on HSC T 1990 - 2004: allogeneic




EBMT Activity survey on HSCT 1990 - 2004: autologous



EBMT Activity survey on HSCT in 2004: patient and transplant numbers


Allogeneic HSCT



7407 1st. HSCT

8956 Total HSCT

Autologous HSCT



14809 1st. HSCT

17638 Total HSCT


First transplants

Retransplants


Additional transplants



Absolute numbers of HSCCT by donor type and main indication: 2004






Relative proportion of donor type by main indication: 2004



HSCT - rates in Europe 2004




Total transplants (1st)

per 10 million 2004



HSCT - rates in Europe 2004




Total allogeneic (1st.)
transplants per 10 million
2004



HSCT - rates in Europe 2004

Total autologous (1st.)
transplants per 10 million



2004



HSCT - rates in Europe 2004

Total unrelated (1st.)
transplants per 10 million

2004



HSCT - rates in Europe 2004

Total teams
per 10 million 2004

